Protalix BioTherapeutics Inc. (PLX)

03:37 AM

Press Release Distribution & PR Platform - ACCESS Newswire

03:37 AM

Apr 24, 2025

PLX’s earnings estimates: Are they on track to meet expectations? - uspostnews.com

Apr 24, 2025

Apr 24, 2025

Protalix BioTherapeutics Inc Inc. (PLX) Price Performance: A Technical Analysis Perspective - investchronicle.com

Apr 24, 2025

Apr 24, 2025

Protalix CFO Eyal Rubin to resign in six months By Investing.com - Investing.com Nigeria

Apr 24, 2025

Apr 23, 2025

Protalix BioTherapeutics' CFO Rubin to Leave - MarketWatch

Apr 23, 2025

Apr 23, 2025

Protalix stock soars to 52-week high, hits $2.76 By Investing.com - Investing.com South Africa

Apr 23, 2025

Apr 23, 2025

Eyal Rubin Resigns As CFO Of Protalix BiotherapeuticsSEC Filing - marketscreener.com

Apr 23, 2025

Apr 23, 2025

Protalix CFO Eyal Rubin to resign in six months - Investing.com

Apr 23, 2025

Apr 23, 2025

Protalix stock soars to 52-week high, hits $2.76 - Investing.com

Apr 23, 2025

Apr 23, 2025

The growth track for Protalix BioTherapeutics Inc (PLX) has changed recently - Sete News

Apr 23, 2025

Apr 10, 2025

Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline - Seeking Alpha

Apr 10, 2025

Apr 10, 2025

Fabry Disease Treatment Market Opportunity and Forecast Report 2025-2034 Featuring Amicus Therapeutics, Avrobio, Freeline, Idorsia, ISU Abxis, JCR, Novartis, Pfizer, Protalix, Sanofi, Takeda, Viatris - Yahoo Finance

Apr 10, 2025

Apr 06, 2025

Protalix BioTherapeutics to Hold Fourth Quarter and Full-Year 2019 Financial and Business Results Conference Call on March 12, 2020 - BioSpace

Apr 06, 2025

Apr 04, 2025

Fabry Disease Treatment Market Deep Research 2025-2032 | - openPR.com

Apr 04, 2025

Apr 01, 2025

Virtu Financial LLC Has $64,000 Stock Holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World

Apr 01, 2025

Mar 26, 2025

[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.

Mar 26, 2025

Mar 26, 2025

Protalix Biotherapeutics is developing innovative treatments for rare diseases with its proprietary ProCellEx plant cell expression system - Proactive financial news

Mar 26, 2025

Mar 26, 2025

Protalix BioTherapeutics And 2 Other Promising Penny Stocks - simplywall.st

Mar 26, 2025

Mar 24, 2025

Protalix to present at iAccess Alpha Virtual Investment Conference 2025 - Proactive financial news

Mar 24, 2025

Mar 24, 2025

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 - Financial Times

Mar 24, 2025

Mar 22, 2025

Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now? - Insider Monkey

Mar 22, 2025

Mar 21, 2025

Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive Investors

Mar 21, 2025

Mar 21, 2025

Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipelineICYMI - Proactive financial news

Mar 21, 2025

Mar 21, 2025

FY2025 Earnings Estimate for PLX Issued By Zacks Small Cap - Defense World

Mar 21, 2025

Mar 20, 2025

Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com - Defense World

Mar 20, 2025

Mar 20, 2025

Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge - markets.businessinsider.com

Mar 20, 2025

Mar 18, 2025

Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors

Mar 18, 2025

Mar 18, 2025

Protalix Biotherapeutics gains momentum: analysts see long-term upside - Proactive Investors USA

Mar 18, 2025

Mar 18, 2025

Protalix BioTherapeutics pipeline eyes gout treatment as financial strength fuels future growth - Proactive financial news

Mar 18, 2025

Mar 18, 2025

Protalix BioTherapeutics : Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting - Marketscreener.com

Mar 18, 2025

Mar 18, 2025

Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate - Proactive Investors UK

Mar 18, 2025

Mar 18, 2025

Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 18, 2025

Mar 18, 2025

PLX: 2024 Results - Yahoo Finance

Mar 18, 2025

Mar 18, 2025

Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... - Yahoo

Mar 18, 2025

Mar 18, 2025

Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... By GuruFocus - Investing.com Canada

Mar 18, 2025

Mar 18, 2025

Protalix BioTherapeutics Reports Record Revenue and Clinical Progress - TipRanks

Mar 18, 2025

Mar 17, 2025

Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth By Investing.com - Investing.com Canada

Mar 17, 2025

Mar 17, 2025

Protalix plans Phase 2 for PRX-115 in H2 2025, projects higher royalty revenues by 2030 - MSN

Mar 17, 2025

Mar 17, 2025

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond - Benzinga

Mar 17, 2025

Mar 17, 2025

Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com

Mar 17, 2025

Mar 17, 2025

Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth - Investing.com

Mar 17, 2025

Mar 17, 2025

Protalix BioTherapeutics Inc. (DE) (PLX) reports earnings - Quartz

Mar 17, 2025

Mar 17, 2025

Protalix Q4 Earnings Fall, Stock Up In Pre-market - Nasdaq

Mar 17, 2025

Mar 17, 2025

Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results - GuruFocus.com

Mar 17, 2025

Mar 14, 2025

StockNews.com Upgrades Protalix BioTherapeutics (NYSE:PLX) to “Strong-Buy” - Defense World

Mar 14, 2025

Mar 10, 2025

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference - Kilgore News Herald

Mar 10, 2025

Mar 10, 2025

Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 - Quantisnow

Mar 10, 2025

Mar 10, 2025

Protalix BioTherapeutics to Report FY2024 Earnings on March 17 - Stock Titan

Mar 10, 2025

Mar 09, 2025

Protalix BioTherapeutics (NYSE:PLX) and INmune Bio (NASDAQ:INMB) Head-To-Head Review - The AM Reporter

Mar 09, 2025